The effects of sacubitril/valsartan compared to valsartan on left ventricular remodelling in patients with asymptomatic left ventricular systolic dysfunction after myocardial infarction: a randomised, double-blinded, active-comparator, cardiac-MR based trial.
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 26 Nov 2019
Price : $35 *
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Valsartan
- Indications Heart failure; Left ventricular dysfunction
- Focus Proof of concept; Therapeutic Use
- Acronyms RECOVER-LV
- 22 Nov 2019 Status changed from not yet recruiting to active, no longer recruiting.
- 15 Jun 2018 New trial record